ERBB2 and neoplasm: This proof‐of‐concept study revealed that the combined inhibition of EGFR and HER2 induced long‐lasting tumour regression, suggesting promising therapeutic opportunities for mCRC patients that are resistant to cetuximab (Bertotti et al, 2011).